The human immunodeficiency viruses (HIV) are two species of Lentivirus that infect humans. Over time, they cause acquired immunodeficiency syndrome (AIDS), a condition in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. Without treatment, the average survival time after infection with HIV is estimated to be 9 to 11 years, depending on the HIV subtype.
The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.
The global pandemic of HIV/AIDS began in 1981, and is an ongoing worldwide public health issue. According to the World Health Organization (WHO), by 2023, HIV/AIDS had killed approximately 40.4 million people, and approximately 39 million people were infected with HIV globally. Of these, 29.8 million people (75%) are receiving antiretroviral treatment. There were about 630,000 deaths from HIV/AIDS in 2022. The 2015 Global Burden of Disease Study estimated that the global incidence of HIV infection peaked in 1997 at 3.3 million per year. Global incidence fell rapidly from 1997 to 2005, to about 2.6 million per year. Incidence of HIV has continued to fall, decreasing by 23% from 2010 to 2020, with progress dominated by decreases in Eastern Africa and Southern Africa. As of 2023, there are about 1.3 million new infections of HIV per year globally.
HIV/AIDS in India is an epidemic. The National AIDS Control Organisation (NACO) estimated that 3.14 million people lived with HIV/AIDS in India in 2023. Despite being home to the world's third-largest population of persons with HIV/AIDS, the AIDS prevalence rate in India is lower than that of many other countries. In 2016, India's AIDS prevalence rate stood at approximately 0.30%—the 80th highest in the world. Treatment of HIV/AIDS is via a combination of antiretroviral drugs and education programs to help people avoid infection.
Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is the use of antiviral drugs as a strategy for the prevention of HIV/AIDS by people that do not yet have HIV/AIDS. PrEP is one of a number of HIV prevention strategies for people who are HIV-negative but who have a higher risk of acquiring HIV, including sexually-active adults who are at increased risk of contracting HIV, people who engage in intravenous drug use, and serodiscordant sexually-active couples.
The Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients' needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases, notably leishmaniasis, sleeping sickness, Chagas disease, malaria, filarial diseases, mycetoma, paediatric HIV, cryptococcal meningitis, hepatitis C, and dengue. DNDi's malaria activities were transferred to Medicines for Malaria Venture (MMV) in 2015.
Twentieth-century art—and what it became as modern art—began with modernism in the late nineteenth century.
Gregg Gonsalves is a global health activist, an epidemiologist, an associate professor at Yale School of Public Health and an associate professor (adjunct) at Yale Law School. As well as being co-director of Yale Law School's Global Health Justice Partnership, Gonsalves is the public health correspondent of the progressive magazine The Nation.
HIV in pregnancy is the presence of an HIV/AIDS infection in a woman while she is pregnant. There is a risk of HIV transmission from mother to child in three primary situations: pregnancy, childbirth, and while breastfeeding. This topic is important because the risk of viral transmission can be significantly reduced with appropriate medical intervention, and without treatment HIV/AIDS can cause significant illness and death in both the mother and child. This is exemplified by data from The Centers for Disease Control (CDC): In the United States and Puerto Rico between the years of 2014–2017, where prenatal care is generally accessible, there were 10,257 infants in the United States and Puerto Rico who were exposed to a maternal HIV infection in utero who did not become infected and 244 exposed infants who did become infected.
The San Francisco AIDS Foundation (SFAF) is a nonprofit organization dedicated to providing services for people with HIV/AIDS, with a mission to end the AIDS epidemic in the United States. They were founded in 1982, at the beginning of the AIDS epidemic. SFAF is one of the largest and oldest community-based AIDS service organizations in the United States. SFAF has an 87.67% overall rating, and a 97% accountability & transparency rating, at Charity Navigator.
Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing illness, death and transmission was first proposed in 2000 by Garnett et al. The term is often used to talk about treating people that are currently living with human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) to prevent illness, death and transmission. Although some experts narrow this to only include preventing infections, treatment prevents illnesses such as tuberculosis and has been shown to prevent death. In relation to HIV, antiretroviral therapy (ART) is a three or more drug combination therapy that is used to decrease the viral load, or the measured amount of virus, in an infected individual. Such medications are used as a preventative for infected individuals to not only spread the HIV virus to their negative partners but also improve their current health to increase their lifespans. When taken correctly, ART is able to diminish the presence of the HIV virus in the bodily fluids of an infected person to a level of undetectability. Consistent adherence to an ARV regimen, monitoring, and testing are essential for continued confirmed viral suppression. Treatment as prevention rose to great prominence in 2011, as part of the HPTN 052 study, which shed light on the benefits of early treatment for HIV positive individuals.
David DuPuy Celentano is a noted epidemiologist and professor who has contributed significantly to the promotion of research on HIV/AIDS and other sexually transmitted infections (STIs). He is the Charles Armstrong chair of the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. He holds joint appointments with the school’s departments of Health Policy and Management, Health Behavior and Society, and International Health, and the Johns Hopkins University School of Medicine’s Division of Infectious Diseases.
Sharon Ruth Lewin is an Australian infectious diseases expert who is the inaugural Director of The Peter Doherty Institute for Infection and Immunity and the Cumming Global Centre for Pandemic Therapeutics. She is also a Melbourne Laureate Professor of Medicine at The University of Melbourne, and the current president of the International AIDS Society (IAS).
Lisa Maher is Professor and head of Viral Hepatitis Epidemiology, at the Kirby Institute for Infection and Immunity, at the University of New South Wales and was made Member of the Order of Australia in 2015. She was awarded an Elizabeth Blackburn Fellowship, in Public Health from the NHMRC, in 2014. She is a fellow of the Australian Academy of Health and Medical Sciences.
YR Gaitonde Centre for AIDS Research and Education (YRGCARE) is a non-profit organisation in India working in the domain of HIV/AIDS. The organisation was founded by Dr Suniti Solomon in 1993. As reported in 2018, YRGCARE had provided HIV prevention and treatment related services to about 21,000 people in India who were infected by HIV. After Dr Suniti Solomon died, Dr Sunil Solomon leads YRGCARE.
Chloe Meave Orkin is a British physician and Professor of HIV/AIDS medicine at Queen Mary University of London. She works as a consultant at the Royal London Hospital, Barts Health NHS Trust. She is an internationally renowned expert in HIV therapeutics and led the first phase III clinical trial of injectable anti-retrovirals. She is immediate past chair of the British HIV Association, where she championed the Undetectable=Untransmittable (U=U) campaign within the United Kingdom. She is president elect of the Medical Women's Federation. Orkin is gay and was on the Top 100 Lesbian influencer lists in both the UK and in the US in 2020. She considers herself a medical activist and much of her work focuses on inequalities in healthcare and in Medicine.
Etheldreda Nakimuli-Mpungu is a professor, researcher, epidemiologist and psychiatrist at the Department of Psychiatry in the Faculty of Medicine, Makerere University in Uganda. Her research is particularly focused on supportive group psychotherapy as a first-line treatment for depression in people with HIV. She is one of only five recipients of the Elsevier Foundation Award for Early Career Women Scientists in the Developing World in Biological Sciences, as well as listed at one of the BBC's 100 Women in 2020.
Godefridus Johannes Petrus "Frits" van Griensven is a pioneering Dutch scientist in epidemiology, sociology and public health. Most of his work is on addressing the HIV epidemic among men who have sex with men and other HIV key populations.
Undetectable = Untransmittable (U=U) is a message used in HIV campaigns. It means that if someone has an undetectable viral load, they cannot sexually transmit HIV to others. U=U is supported by numerous health groups and organisations worldwide, including the World Health Organization (WHO). The validity of U=U has been proven through many clinical trials involving thousands of couples. U=U is also used as an HIV prevention strategy: if someone is undetectable, they cannot pass it further and hence, prevent the virus from spreading. This is known as Treatment as Prevention (TasP).
Pre-exposure prophylaxis (PrEP), is the use of medications to prevent the spread of disease in people who have not yet been exposed to a disease-causing agent. Vaccination is the most commonly used form of pre-exposure prophylaxis; other forms of pre-exposure prophylaxis generally involve drug treatment, known as chemoprophylaxis. Examples include taking medication to prevent infection by malaria or HIV. In particular, the term PrEP is now synonymous in popular usage with the use of pre-exposure prophylaxis for HIV prevention.
